Management of infirmity through medication is entering a new era in which growing number of novel drug delivery systems are being employed and are available for therapeutic use. Oral sustained release gastro-retentive dosage forms (GRDFs) offer many advantages for drugs with absorption from upper parts of gastrointestinal tract and for those acting locally in the stomach, improving the bioavailability of the medication. Floating Drug Delivery Systems (FDDS) is one amongst the GRDFs used to achieve prolonged gastric residence time. The purpose of writing this review on floating drug delivery systems (FDDS) was to compile the recent literature with special focus on the principal mechanism of floatation to achieve gastric retention. The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail. This review also summarizes the in vitro techniques, in vivo studies to evaluate the performance and application of floating systems, and applications of these systems.
INTRODUCTION
Gastric emptying of dosage forms is an extremely variable process and ability to prolong and control emptying time is a valuable asset for dosage forms, which reside in the stomach for a longer period of time than conventional dosage forms. Several difficulties are faced in designing controlled release systems for better absorption and enhanced bioavailability. One of such difficulties is the inability to confine the dosage form in the a complex procedure and is subject to many variables. It is widely acknowledged that the extent of gastrointestinal tract drug absorption is related to contact time with the small intestinal mucosa. Thus small intestinal transit time is an important parameter for drugs that are incompletely absorbed [1] .
Delivery of drugs at a specific region in gastrointestinal tract, the so called absorption window needs the development of gastro retentive dosage forms [1] [2] . The attempts to develop gastro retentive drug delivery systems may be largely divided into two classes:
Those that rely on the natural physiology of the gastrointestinal tract and those that are designed to overcome it The main approaches that have been examined for gastro retentive dosage forms (GRDFs) are: low density of GRDF that cause buoyancy above gastric fluid (Floating system), high density GRDF which retain the dosage form in the body of stomach. Gastric emptying of dosage forms is an extremely variable process and ability to prolong and control emptying time is a valuable asset for dosage forms, which reside in the stomach for a longer period of time than conventional dosage forms. Several difficulties are faced in designing controlled release systems for better absorption and enhanced bioavailability. One of such difficulties is the inability to confine the dosage form in the desired area of the gastrointestinal tract. Drug absorption from the gastrointestinal tract is a complex procedure and is subject to many variables. It is widely acknowledged that the extent of gastrointestinal tract drug absorption is related to contact time with the small intestinal mucosa [3] .Thus small intestinal transit time is an important parameter for drugs that are incompletely absorbed. Gastroretensive systems can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug waste and improves solubility for drugs that are less soluble in a high pH environment. It has applications also for local drug delivery to the stomach and proximal small intestines. Gastro retention helps to provide better availability of new products with new therapeutic possibilities and substantial benefits for patients [4] . Gastro retention helps to provide better availability of new products with suitable therapeutic activity and substantial benefits for patients. This mode of administration would best achieve the known pharmacokinetic and pharmacodynamic advantages of CR-DFs of these drugs.
The need for gastroretentive dosage forms (GRDFs) has led to extensive efforts in both academia and industry towards the development of such drug delivery systems. The idea of gastroretention stems from the need to localize drugs at a specific region of G.I. tract such as stomach in the body. Gastroretention is essential for drugs that are absorbed from the stomach, drugs that are poorly soluble or degraded by the higher pH of intestine, and drugs with an absorption which can be modified by changes in gastric emptying time.
Gastroretentive dosage forms are also useful for local as well as sustained drug delivery for certain conditions, like H. pylori infection which is the cause of peptic ulcers. To formulate a successful stomach specific or gastroretentive drug delivery system, several
techniques are currently used such as hydrodynamically balanced systems (HBS) / floating drug delivery system [3] , lowdensity systems [5] [6] [7] , mucoadhesive systems [8] , high density systems [9] [10] [11] , superporous hydrogels & magnetic systems.
Criteria for selection of drug candidate for GRDF
1. Drugs required to exert local therapeutic action in the stomach: e.g. misoprostol, 5
Flurouracil,and antacids Preparations, anti Helicobacter pylori agents and certain enzymes. stomach and prevents the system from passing through remainder of GIT. The different grades of HPMC were used to develop the eroding matrix. They concluded that duration of action was dependent on erosion rate of the incorporated polymer and the in vitro release of drug from developed device could be maintained up to 20 days [5] . due to reaction between sodium bicarbonate and tartaric acid and formed swollen pills (like balloons) with a density much lesser than 1.0 g/ml. The system was found to float completely within 10 minutes and had a good floating ability independent of pH, viscosity of the medium and drug release in a sustained manner [3] . drug with in the matrix tablet. These have a bulk density lower than gastric fluids and therefore remain floating in the stomach unflattering the gastric emptying rate for a prolonged period. The drug is slowly released at a desired rate from the floating system and after the complete release the residual system is expelled from the stomach. This leads to an increase in the GRT and a better control over fluctuations in plasma drug concentration [11] .
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Intra Gastric Bilayer Floating Tablets:
These are also compressed tablet as shown below and containing two layer i.e., i. Immediate release layer and ii. Sustained release layer.
Multiple Unit type floating pills:
These systems consist of sustained release pills as 'seeds' surrounded by double layers.
The inner layer consists of effervescent agents while the outer layer is of swellable membrane layer. When the system is immersed in dissolution medium at body temp, it sinks at once and then forms swollen pills like balloons, which float as they have lower density. This lower density is due to generation and entrapment of CO2 within the system [11] . These system can be made to float in the stomach because of floatation chamber, which may be a vacum or filled with air or a harmless gas, while drug reservoir is encapsulated inside a microprous compartment [11] .
Figure 4 Intra Gastric Floating Gastrointestinal Drug Delivery Device
Inflatable Gastrointestinal Delivery Systems:
In these systems an inflatable chamber is incorporated, which contains liquid ether that gasifies at body temperature to cause the chamber to inflate in the stomach. These systems are fabricated by loading the inflatable chamber with a drug reservoir, which can be a drug impregnated polymeric matrix, then encapsulated in a gelatin capsule. After oral administration, the capsule dissolves to release the drug reservoir together with the inflatable chamber. The inflatable chamber automatically inflates and retains the drug reservoir compartment in the stomach. The drug continuously released from the reservoir into the gastric fluid [10] . 
Intragastric Osmotically Controlled Drug Delivery System:
It is comprised of an osmotic pressure controlled drug delivery device and an inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly disintegrates to release the intragastirc osmotically controlled drug delivery device. The inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug delivery device consists of two components; drug reservoir compartment and an osmotically active compartment. The floating support is also made to contain a bioerodible plug that erodes after a predetermined time to deflate the support. The deflated drug delivery system is then emptied from the stomach [11] .
Figure 6 Intragastric Osmotically Controlled Drug Delivery System
Non Effervescent Floating Drug Delivery System
The non-effervescent FDDS works on the mechanism of polymer swelling, bioadhesion of the polymer to mucosal layer of GI tract. The most commonly used excipients for the preparations of non-effervescent FDDS are gel forming or swellable type hydrocolloids, polysaccharides and matrix forming polymers like polymethacrylates, polycarbonates, polyacrylates, polystyrenes and bioadhesion polymers like chitosan and carbopols. One Hydrodynamically balanced capsules containing mixture of drug and hydrocolloids.
Upon contact with gastric fluid, the capsule shell dissolved in gastric fluid followed by swelling of mixtures, formation of a gelatinous barrier and maintains bulk density less than 1.0, which remained buoyant on the gastric fluid for an extended period of time [4] .
The various types of this system are as [11] :
Single Layer Floating Tablets:
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of less than unity. The air trapped by the swollen polymer confers buoyancy to these dosage forms.
Bilayer Floating Tablets:
A bilayer tablet contain two layer one immediate release layer which release initial dose from system while the another sustained release layer absorbs gastric fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a bulk density of less than unity and thereby it remains buoyant in the stomach [11] .
Alignate Beads:
Multi unit floating dosage forms were developed from freeze-dried calcium alginate.
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping a sodium alginate solution into aqueous solution of calcium chloride, causing precipitation of calcium alginate leading to formation of porous system, which can maintain a floating force for over 12 hours. When compared with solid beads, which gave a short residence time of 1 hour, these floating beads gave a prolonged residence time of more than [7] .
Hollow Microspheres:
Vol Hollow microspheres (microballoons), loaded with drug in their outer polymer shells were prepared by a novel emulsionsolvent diffusion method. The ethanol :
dichloromethane solution of the drug and an enteric acrylic polymer was poured into an agitated aqueous solution of PVA that was thermally controlled at 400C. The gas phase generated in dispersed polymer droplet by evaporation of dichloromethane formed an internal cavity in microsphere of polymer with drug [6] .
Intragastric Floating Drug Delivery Device
The Novel levodopa gastro retentive dosage form based on unfolding polymeric membranes, that combines extended dimensions with high rigidity. It was folded into a large size gelatin capsules. In vitro studies showed that unfolded form reached within 15 minutes after administration and it was confirmed in vivo in beagle dogs. The unfolded form was maintained for at least hours. It was concluded that this dosage form could improve therapy of different narrow absorption window drugs. However, there are possibilities of the polymeric films to get stuck in the esophagus causing extreme discomfort to the patient or drug related injuries and repeated administration of rigid dosage form may result in gastric obstruction [2] . tablets are also evaluated for hardness, weight variation, etc.
For Multiple Unit Dosage Forms (ex: microspheres)
Apart from the In vitro release, duration of floating and in vivo gastro-retention tests, the multiple unit dosage forms are also evaluated for (i) Morphological and dimensional analysis with the aid of scanning electron microscopy (SEM). The size can also be measured using an optical microscope.
(ii) % yield of microspheres: This is calculated from (iii) Entrapment efficiency: The drug is extracted by a suitable method, analysed and is calculated from Gelucire 43/01) are also evaluated for the effect of ageing with the help of Differential Scanning Calorimeter or Hot stage polarizing microscopy [9] .
CHARACTERIZATION PARAMETERS:
Size and shape evaluation:
The particle size and shape plays a major role in determining solubility rate of the drugs and thus potentially its bioavailability. The particle size of the formulation was 
Floating Properties:
Effect of formulation variables on the floating properties of gastric floating drug delivery system was determined by using continuous floating monitoring system and statistical experimental design.
Surface Topography:
The surface topography and structures were determined using scanning electron microscope (SEM, JEOL JSM -6701 F, Japan) operated with an acceleration voltage of 10k.v, Contact angle meter, Atomic force microscopy (AFM), Contact profiliometer.
Determination of Moisture Content:
The water content per se is seldom of interest. Rather, it shows whether a product intended for trade and production has standard properties such as [8] . [3] .
Swelling Studies:
Swelling studies were performed to calculate molecular parameters of swollen polymers. [6] .
Determination of the Drug Content:
Percentage drug content provides how much amount of the drug that was present in the formulation. It should not exceed the limits acquired by the standard monographs. Drug content was determined by using HPLC, HPTLC methods, Near infrared spectroscopy (NIRS), Microtitrimetric methods, Inductively Coupled Plasma Atomic Emission Spectrometer (ICPAES) and also by using spectroscopy techniques [11] .
Percentage Entrapment Efficiency:
Percentage entrapment efficiency was reliable for quantifying the phase distribution of drug in the prepared formulations. Entrapment efficiency was determined by using three methods such as Micro dialysis method, Ultra centrifugation, and pressure Ultra filtration [10] .
In-vitro Release Studies:
In vitro release studies (USP dissolution apparatus (usp-24) lab India disso 2000) were performed to provide the amount of the drug that is released at a definite time period. Release studies were performed by using Franz diffusion cell system and synthetic membrane as well as different types of dissolution apparatus [11] .
Powder X-ray Differaction:
X-ray powder diffraction (Philips analytical, modelpw1710) is the predominant tool for the study of poly-crystalline materials and is eminently suited for the routine characterization of pharmaceutical solids. Samples were irradiated with α radiation and analyzed between 2 oC and 60 oC .The voltage and current used were 30KV and 30mA respectively [2] .
Fourier Transform Infrared Analysis:
Fourier transform infrared spectroscopy (FT-IR, Shimadzu, Model-RT-IR-8300) is a technique mostly used to identify organic, polymeric, and some inorganic materials as well as for functional group determination. Fourier Transform Infrared Analysis (FT-IR) measurements of pure drug, polymer and drugloaded polymer formulations were obtained on FTIR. The pellets were prepared on KBr-press under hydraulic pressure of 150kg/cm2; the spectra were scanned over the wave number range of 3600 to 400 cm-1 at the ambient temperature [5] .
Differential Scanning Calorimetry (DSC):
DSC (Shimadzu, Model-DSC-60/DSC-50/ Metler Toldeo) are used to characterize water of hydration of pharmaceuticals .Thermo grams of formulated preparations were obtained using DSC instrument equipped with an intercooler. Indium/Zinc standards were used to calibrate the DSC temperature and enthalpy scale. The sample preparations were hermitically sealed in an aluminum pan and heated at a constant rate of 10°C/min; over a temperature range of 25° C -65°C. Inert atmosphere was maintained by purging nitrogen gas at the flow rate of 50ml/min [4] . the bioavailability and controlled delivery of many drugs. The increasing sophistication of delivery technology will ensure the development of increase number of gastroretentive drug delivery to optimize the delivery of molecules that exhibit absorption window, low bioavailability and extensive first pass metabolism. FDDS promises to be a potential approach for gastric retention. Although there are number of difficulties to be worked out to achieve prolonged gastric retention, a large number of companies are focusing toward commercializing this technique.
CONCLUSION
